Consistently, targeting IL8 with Repertaxin not only increased the efficacy of Fulvestrant and/or Palbociclib therapy in ER + breast cancer cells, but also restored the sensitivity to tamoxifen, as well as increased the efficacy of Fulvestrant and/or Palbociclib therapy in tamoxifen resistant cells. The gene discussed is ESR1; the disease is breast carcinoma.